PMEF
HRMY icon

Point72 Middle East FZE’s Harmony Biosciences HRMY Stock Holding History

Point72 Middle East FZE’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-5,561
Closed -$182K – 1775
2023
Q1 		$182K Buy
5,561
+1,024
+23% +$46.6K 0.01% 968
2022
Q4 		$250K Buy
+4,537
New +$249K 0.01% 972

Other funds holding HRMY

VM
Valor Management Chicago, Illinois $181M AUM 6.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Point72 Middle East FZE's HRMY Position: Q2 2023 in Review

Point72 Middle East FZE sold out of Harmony Biosciences (HRMY) in Q2 2023, closing a stake of 5,561 shares — an estimated $182K sold.

Point72 Middle East FZE first reported a position in HRMY in Q4 2022 and held it in 2 quarters. The position peaked at $250K in Q4 2022. 211 funds tracked by Wall St. Rank hold HRMY as of Q2 2023.

  • Point72 Middle East FZE reported no remaining Harmony Biosciences position as of Q2 2023 after selling out during the quarter.
  • Point72 Middle East FZE sold 5,561 Harmony Biosciences shares in Q2 2023, an estimated $182K.
  • Point72 Middle East FZE first reported a position in Harmony Biosciences in Q4 2022 and held it in 2 quarters.
  • Point72 Middle East FZE's Harmony Biosciences position peaked at $250K in Q4 2022.
  • 211 funds tracked by Wall St. Rank held Harmony Biosciences as of Q2 2023.

Based on Point72 Middle East FZE's 13F filing for Q2 2023, filed 14 Aug 2023.